Racing Against Rarity: How Indian Contract Research Organizations Are Reshaping the Orphan Drug Pipeline for American Patients
For the roughly 30 million Americans living with rare diseases, the wait for effective treatment can span decades. Indian contract research organizations are quietly compressing that timeline, offering biotech firms the scientific depth, regulatory fluency, and cost efficiency needed to bring orphan drugs to US patients faster than ever before.